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THE INCREASING INCIDENCE OF EXTENDED-SPECTRUM BETA-
LACTAMASE-PRODUCING STRAINS OF ESCHERICHIA COLI AND
KLEBSIELLA PNEUMONIAE
Chao-Tai Lee a, Hung-Ming Chu a, Chin-Lu Chang b. aDepartment of Clinical
laboratory, Tainan Municipal Hospital, Tainan, Taiwan; bCommittee of
Infection Control, Tainan Municipal Hospital, Tainan, Taiwan
Purpose: The incidence of extended-spectrum beta-lactamase (ESBL)-pro-
ducing strains of Escherichia coli and Klebsiella pneumoniae is increasing
worldwide, which may change empiric antibiotic treatment. This study
was conducted to explore the increasing extent of the incidence of ESBL-
producing strains (ESBLPS) in E. coli and K. pneumoniae.
Methods: This was a retrospective study at a regional hospital in southern
Taiwan. From 2009 to 2013, all E. coli and K. pneumoniae isolates from clin-
ical microbiology laboratory were enrolled in this study. ESBLPS were
confirmed by double disk diffusion test.
Results: A total of 15954E. coli and5374K. pneumoniae isolateswere enrolled.
The ESBLPS accounted for 10.7 % (325/3048) and 16.8% (186/1109), 12.1% (362/
2989) and 16.1% (155/963), 13.3% (447/3359) and 19.2% (214/1112), 17.4%
(633/3635) and 20.8% (219/1051), as well as 20.5 % (753/2923) and 20.2%
(230/1139) of E. coli and K. pneumoniae isolates in 2009, 2010, 2011, 2012,
and 2013, respectively. The incidence of ESBLPS of E. coli and K. pneumoniae
was statistically significant difference between 2009 and 2013 (P < 0.05).
Conclusions: As a result of this study, the incidence of ESBLPS of E. coli and
K. pneumniae was statistically significant increase from 2009 to 2013 (10.7%
versus 20.5% in E. coli and 16.8% versus 20.2% in K. pneumoniae). The inci-
dence of ESBLPS of E. coli was lower than that of K. pneumoniae before
2012, but that was similar in 2013. We think that the rapid increase of
ESBLPS of E. coli should be concerned in clinical practice because E. coli
is more frequent organism causing infections than K. pneumoniae.
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REPORT AN ISOLATE OF IMIPENEM-RESISTANT PROTEUS MIRABILIS
Yi-Chu Lo, Chin-Lu Chang. Committee of Infection Control, Tainan Municipal
Hospital, Tainan, Taiwan
Purpose: To report an isolate of imipenem-resistant Protues mirabilis and
investigate the cause of resistance to imipenem.
Methods: An isolate of P. mirabilis was isolated from urine of a patient lived
at nursing home. Disk diffusion testing was used for antimicrobial suscepti-
bility testing and E-test was used to determine the minimal inhibitory con-
centation (MIC) of imipenem. The results were interpreted according to
the criteria recommended by the Clinical Laboratory Standards Institute
2014. Polymerase chain reaction (PCR) and sequencing were used to detect
aˆ-lactamase, including carbapenemase, and porin mutation.
Results: Antimicrobial susceptibility testing revealed the isolatewas resistant to
cefazolin, cefuroxime, cefoxitin, ceftriaxone, ceftazidime, ampicillin-sulbac-
tam, piperacillin-tazobactam, gentamicin, amikacin, levofloxacin, trimethor-
pim-sulfamethoxazole, and imipenem; and sensitive to cefepime, ertapenem,
and meropenem. The MIC of imipenem was >32 mg/ml. PCR and sequencing
revealed only blaCMY-2 was detected and some mutation of ompF was present.
Conclusions: As a result of this study, the cause of the P. mirabilis resistant
to aˆ-lactams except cefepime and carbapenems was producing of CMY-2 aˆ-
lactamase, and resistant to imipenem was producing CMY-2 aˆ-lactamase
combined with porin deficiency. We think imipenem-resistant P. mirabilis
is worthy of attention. If it is also resistant to other carbapenems, it may
become pandrug-resistant organism because P. mirabilis is intrinsically resis-
tant to the two last resort antibiotics, namely tigecycline and colistin.PS 2-474
EVALUATE THE SENSITIVITY AND SPECIFICITY OF DETECTING
CARBAPENEM-RESISTANT ENTEROBACTERICEAE BY ERTAPENEM
Chin-Lu Chang. Committee of Infection Control, Tainan Municipal Hospital,
Tainan, Taiwan
Purpose: According to the definition of the U.S. Centers for Disease Control and
Prevention, carbapenem-resistant enterobactericeace (CRE) are defined as
enterobactericeae that are nonsusceptible to imipenem, meropenem, ordoripenem; and resistant to third-generation cephalosporins, including cefotax-
ime, ceftriaxone, and ceftazidime. For Proteus spp., Providencia spp., andMor-
ganella morgannii, those must be also nonsusceptible to other carbapenems
except imipenem. Ertapenem is known as the most sensitive antibiotic for
detecting CRE, but the specificity is low. This study was conducted to evaluate
theextent of the sensitivity and specificityof detectingCREbyertapenemalone.
Methods: At a regional hospital, from September 2013 to August 2014, all enter-
obactericeae nonsusceptible to one of carbapenems (including ertapenem, imi-
penem, meropenem, and doripenem) were enrolled in this study. In those
isolates, if theyfulfilledtheabove-mentionedcriteria, theyweredefinedasCRE.
Results: A total of 103 isolates, including 38 CRE and 65 non-CRE, were
enrolled. Of all CRE, 37 were resistant to ertapenem and one was susceptible
to ertapenem. Of all non-CRE, 53 were resistant to ertapenem and 12 were
susceptible to ertapenem. The sensitivity and specificity of detecting CRE by
ertapenem alone was 97.4% (37 of 38) and 18.5% (12 of 65), respectively.
Conclusions: As a result of this study, ertapenem alone had 97.4% sensitiviity
of detecting CRE, but only had 18.5% specificity. Accordingly, If CRE are
defined as enterobactericeae that are nonsusceptible to ertapenem alone,
which will have an overestimate of CRE up to 81.5%.
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IN-VITRO ACTIVITIES OF COMBINATION BETWEEN TIGECYCLINE,
COLISTIN, AND FOSFOMYCIN AGAINST KLEBSIELLA PNEUMONIAE (KP)
ISOLATES WITH EXTENDED-SPECTRUM b-LACTAMASE (ESBL) PHENOTYPE
Yee-Huang Ku a, Wen-Liang Yu b, Mei-Feng Lee c, Yin-Ching Chuang a,c.
aDepartment of Medicine, Chi Mei Medical Center-Liou Ying, Tainan,
Taiwan; bDepartment of Intensive Care Medicine, Chi-Mei Medical Center,
Tainan, Taiwan; cDepartment of Medical research, Chi-Mei Medical Center,
Tainan, Taiwan
Purpose: The emergence of carbapenem-resistant Enterobacteriaceae has
severely limited the option of antimicrobial therapy against ESBL-producers.
We aimed to evaluate the potentially alternative antimicrobial strategy for
treating infections caused by ESBL-producing KP isolates using non-carbape-
nem regimens.
Material and methods: We investigated the synergism between any two of
tigecycline, colistin and fosfomycin against 6 clinical isolates of ESBL-KP
strains (designed KP 357, 402, 403, 420, 324, 441) from patients hospitalized
in a medical center in southern Taiwan. Synergism was evaluated by time-kill
studies. The in-vitro activities of tigecycline, colistin and fosfomycin was
tested by using 1/2 x MIC and 1/4 x MIC for each drug concentration alone
or for any two drugs. The standard inoculum of bacterial densities was a sus-
pension containing 5  105 CFU/mL. Bactericidal activity was defined as aS
3-log10 CFU/mL decrease at least lasting for 24 hours in viable cell counts
compared to the original inoculum. Synergistic effect was defined as S 3-
log10 CFU/mL compared to the most active drug.
Results: Only 2 strains (KP 357 and 441) reached synergistic effects by 1/2
MIC of tigecycline plus fosfomycin. Only 2 strains (KP 403 and 423) reached
synergistic effects by 1/2 MIC of colistin plus fosfomycin. All 6 isolates
reached synergistic effects by 1/2 MIC of tigecycline plus colistin, and
even 4 strains (KP 357, 410, 423 and 441) reached synergistic effects by 1/
4 MIC of tigecycline plus colistin.
Conclusions: The combination activity of tigecycline and colistin showed the
most in-vitro synergistic effects against the tested ESBL-KP isolates.PS 2-476
CEFEPIME THERAPY FOR URINARY TRACT INFECTIONS CAUSED BY
EXTENDED-SPECTRUM b-LACTAMASES (ESBLS)-PRODUCING ESCHERICHIA
COLI: FROM EX VIVO MODEL OF URINARY BACTERICIDAL ACTIVITY TO
CLINICAL APPLICATION
Poh-Chang Tang a,b, Ching-Lung Lo a, Tzu-lun Hung a, Chin-Shiang Tsai a,
Nan-Yao Lee a,c. aDepartment of Internal Medicine, National Cheng Kung
University Hospital, Taiwan; bDepartment of Internal Medicine, Tainan
Municipal Hospital, Taiwan; cSchool of Medicine, National Cheng Kung
University, Tainan, Taiwan
Background and purpose: The clinical role of cefepime therapy for urinary
tract infections (UTIs) caused by so called susceptible Extended-Spectrum b-
Lactamases (ESBL)-producing Escherichia coli remains unclear. The aim of
this investigation was to assess the urinary bactericidal activity of cefepime
against ESBL-producing E. coli isolates in ex vivo model.
